Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Result of Subscription

3 Dec 2024 13:24

RNS Number : 6458O
EMV Capital PLC
03 December 2024
Β 

For immediate release

Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (UK MAR). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

Β 

EMV Capital plc

Β 

("EMV Capital" or the "Company" or the "Group")

Β 

Result of Subscription

Β 

Successful Subscription to raise Β£880,000

Β 

EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, is pleased to announce, following its announcement made earlier today (Impact Announcement), the successful completion of the Subscription at the Issue Price of Β£0.50 per New Share for 1,760,000 New Shares, raising in aggregate Β£880,000 from new and existing shareholders. Terms defined in the Impact Announcement have the same meanings in this announcement.

Retail Offer

As announced earlier today, the Company also launched the Retail Offer through the Winterflood Retail Access platform to raise up to Β£620,000. The Retail Offer is expected to close at 4:30 p.m. on 4 December 2024, or such later time and date as the Company and Winterflood may agree, the results of which are expected to be announced on or around 5 December 2024.

Related party transactions

Director participation

Ilian Iliev (Chief Executive Officer) has participated in the Subscription by subscribing for 200,000 New Shares at the Issue Price, with payment therefor to be settled by releasing the Company from Β£100,000 of the annual bonus awarded to him for the year ended 31 December 2023, such amount being c.80 per cent. of such annual bonus.

Charles Spicer (Non-Executive Chair) and Ed Hooper (Executive Director) intend to participate in the Retail Offer by subscribing for New Shares (20,000 and 180,000 respectively) at the Issue Price via their respective Self-Invested Personal Pensions. Further details will be included in the announcement of the result of Retail Offer.

Ilian Iliev is deemed to be a related party pursuant to Rule 13 of the AIM Rules for Companies and his participation in the Fundraising (as described above) is a related party transaction for the purposes of such Rule (Director RPT).

The table below summarises the interests of Ilian Iliev in the Fundraising.

Existing beneficial shareholding

New Shares subscribed for

Shareholding on Admission

Shareholding as a percentage of the enlarged share capital upon Admission*

3,661,457

200,000

3,861,457

14.11%

*assuming the Retail Offer is fully subscribed

The information below the heading 'About EMV Capital plc (EMVC)', set out in accordance with the requirements of MAR, provides further detail.

Substantial Shareholder participation

A Beckman plc SSAS (Small Self Administered Pension Scheme), which is associated with Melvin Lawson, a substantial shareholder in the Company, has participated in the Subscription by subscribing for 100,000 New Shares at the Issue Price (Substantial Shareholder Participation). The Substantial Shareholder Participation is deemed to be a related party transaction pursuant to the AIM Rules for Companies (Shareholder RPT).

AIM Rule 13 fair and reasonable opinion

Jonathan Robinson, being the Director who is independent of the Director RPT and the Shareholder RPT (together Related Party Transactions), having consulted with the Company's nominated adviser, Panmure Liberum Limited, considers the terms of the Related Party Transactions to be fair and reasonable insofar as the Company's shareholders are concerned.

Admission

Application will be made to London Stock Exchange plc for the admission to trading on AIM of the Subscription Shares and such number of Retail Offer Shares as are subscribed for pursuant to the Retail Offer (Admission). It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on or around 9 December 2024.

Β 

The person responsible for arranging the release of this announcement on behalf of the Company is Ed Hooper, Executive Director and General Counsel of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

-ends-

Β 

For more information, please contact:

Β 

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

Β 

Β 

Panmure Liberum (UK) Limited (NOMAD and Broker)

+44 (0)20 7886 2500

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

Β 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce

Β 

About EMV Capital plc (EMVC)

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

Β 

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early stage IP-rich companies.

Β 

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

Β 

Β· capital-efficient investments through Group balance sheet;

Β· fund management of the Evergreen EIS and Martlet Capital Funds;

Β· syndicated investments leveraging its network of third-party investors.

Β 

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Β 

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

Β 

www.emvcapital.com

Β 

Β 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Name

Dr Ilian Iliev

2

Reason for the notification

a)

Position/status

Director

b)

Β 

Initial notification /Amendment

Initial Notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EMV Capital plc

b)

LEI

213800N5WD46G1Y7I458

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

EMVC 5p Ordinary Shares

Β 

Β 

GB00BN4R5Q82

b)

Nature of the transactionΒ 

Subscription for new Ordinary Shares

c)

Β 

Price(s) and volume(s)

Β 

Β 

Price(s)

Β 

Volume(s)

Β£0.50

200,000 shares

Β 

d)

Β 

Aggregated information

Β - Aggregated volume

Β 

Β - Price

Β 

N/a

e)

Β 

Date of the transaction

3 December 2024

f)

Β 

Place of the transaction

UK AIM

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHZZMGZFFMGDZM
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.